Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315.
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS‐CoV‐2 infection and hospitalization, but not ICU admission and death: real‐life data from a large cohort during red‐zone declaration. Dermatol Ther. 2020;33(5):2–7.
   Web of Science ®Google Scholar
• Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373–374.
   PubMed Web of Science ®Google Scholar
• Queiro Silva R, Armesto S, González Vela C, et al. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. Dermatol Ther. 2020;33(6):e13961.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Harding-Oredugba G, Griffiths CEM, et al. Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-Centre cross-sectional study. Br J Dermatol. 2021;185(2):441–443.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, PSO-BIO-COVID study group, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21(2):271–277.
   PubMed Web of Science ®Google Scholar
• Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, BIOBADADERM Study Group, et al. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a biobadaderm cohort analysis. J Am Acad Dermatol. 2021;84(2):513–517.
   PubMed Web of Science ®Google Scholar
• Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(October):724–736.
   Google Scholar
• Gelfand JM, Armstrong AW, Bell S, et al. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2—advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021;84(5):1254–1268.
   PubMed Web of Science ®Google Scholar
• Izadi Z, Brenner EJ, Mahil SK, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with Immune-Mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639–17.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Yates M, Langan SM, PsoProtect, CORE-UK study groups, et al. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. *Br J Dermatol. 2021;185(1):80–90.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Dand N, Mason KJ, PsoProtect study group, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study. J Allergy Clin Immunol. 2021;147(1):60–71. Jan
   PubMed Web of Science ®Google Scholar
• Bragazzi NL, Riccò M, Pacifico A, et al. COVID-19 knowledge prevents biologics discontinuation: data from an italian multicenter survey during RED-ZONE declaration. Dermatol Ther. 2020;33(4):e13508.
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Isoletta E, Barak O, et al. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone. Dermatol Ther. 2020;33(6):1–5.
   Web of Science ®Google Scholar
• Penso L, Dray-Spira R, Weill A, et al. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France*. Br J Dermatol. 2022;186(1):59–68.
   PubMed Web of Science ®Google Scholar
• Jones ME, Kohn AH, Pourali SP, et al. The use of biologics During the COVID-19 pandemic. Dermatol Clin. 2021;39(4):545–553. Oct
   PubMed Web of Science ®Google Scholar
• Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53(January):38–42.
   PubMedGoogle Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7–e47.
   Web of Science ®Google Scholar
• Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329.
   PubMed Web of Science ®Google Scholar
• Luo XH, Zhu Y, Mao J, et al. T cell immunobiology and cytokine storm of COVID-19. Scand J Immunol. 2021;93(3):0–2.
   Web of Science ®Google Scholar
• Ma Q, Liu J, Liu Q, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(12):e2137257–18.
   PubMed Web of Science ®Google Scholar
• Alejo JL, Mitchell J, Chang A, et al. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA - J Am Med Assoc. 2022;327(11):1083–1085.
   PubMed Web of Science ®Google Scholar
• Muecksch F, Wise H, Batchelor B, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis. 2021;223(3):389–398.
   PubMed Web of Science ®Google Scholar
• Van Elslande J, Oyaert M, Ailliet S, et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol. 2021;136:104763–104765.
   Web of Science ®Google Scholar
• Shirin T, Bhuiyan TR, Charles RC, et al. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. Int J Infect Dis. 2020;101:220–225.
   PubMed Web of Science ®Google Scholar